

## Review Article

# Ribosomes: An Exciting Avenue in Stem Cell Research

Zhenzhen Han, Qi Zhang, Yanbo Zhu, Jingcheng Chen, and Wei Li 

Stem Cell and Cancer Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, Jilin 130021, China

Correspondence should be addressed to Wei Li; [jdyylw@163.com](mailto:jdyylw@163.com)

Received 9 April 2020; Revised 12 June 2020; Accepted 16 June 2020; Published 6 July 2020

Academic Editor: shuibin lin

Copyright © 2020 Zhenzhen Han et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Stem cell research has focused on genomic studies. However, recent evidence has indicated the involvement of epigenetic regulation in determining the fate of stem cells. Ribosomes play a crucial role in epigenetic regulation, and thus, we focused on the role of ribosomes in stem cells. Majority of living organisms possess ribosomes that are involved in the translation of mRNA into proteins and promote cellular proliferation and differentiation. Ribosomes are stable molecular machines that play a role with changes in the levels of RNA during translation. Recent research suggests that specific ribosomes actively regulate gene expression in multiple cell types, such as stem cells. Stem cells have the potential for self-renewal and differentiation into multiple lineages and, thus, require high efficiency of translation. Ribosomes induce cellular transdifferentiation and reprogramming, and disrupted ribosome synthesis affects translation efficiency, thereby hindering stem cell function leading to cell death and differentiation. Stem cell function is regulated by ribosome-mediated control of stem cell-specific gene expression. In this review, we have presented a detailed discourse on the characteristics of ribosomes in stem cells. Understanding ribosome biology in stem cells will provide insights into the regulation of stem cell function and cellular reprogramming.

## 1. Introduction

Ribosomes are subcellular cytoplasmic biomolecules composed of rRNA and dozens of proteins. Ribosome sedimentation coefficients in eukaryotic cells and prokaryotic cells are 80S and 70S, respectively. Ribosomes primarily participate in translation, but recent research shows their involvement in multiple biological processes, such as cellular proliferation, differentiation, homeostasis, and development of cancer (these are known as “heterogeneous ribosomes”) [1, 2]. The ribosome filter hypothesis posits that, besides constituting the translation machinery, ribosomes influence the selective expression of mRNAs, thereby differentially regulating cellular function [3]. The efficiency of ribosome biosynthesis depends on specific environments, thereby differentially regulating the function of various cells, such as stem cells. Self-renewal is an attribute of stem cells that requires high translation efficiency [4–8]. Inhibiting translation of genes using transcriptional repressors leads to reduced stemness [4]. Hematopoietic stem cells also require significant ribosomal activity [9]. Cells can internalize ribosomes via trypsin-activated endocytosis to generate cell clusters similar to

embryonic bodies expressing pluripotency markers [10]. It has been reported that ribosomes regulate stem cell differentiation and embryonic growth [11]; however, the mechanisms involved in this process remain to be understood. This review summarizes characteristics of “stem ribosomes”.

*1.1. Ribosome-Mediated mRNA Translation.* mRNA translation primarily involves 3 steps: initiation, elongation, and termination [12]. And the mRNAs have dynamic interactions of the small and large subunits of the ribosome, aided by multiple auxiliary factors during the process of translation [13]. Ribosomes read the codons (genetic code) in the mRNA; each codon corresponds to the addition of an amino acid [14]. Initiation is an important rate-limiting step in translation [15]. During this step, initiation factors facilitate the recruitment of the 40S subunit to the mRNA 5' end, scanning of the 5' untranslated region (UTR), start codon recognition and 80S subunit joining to form an elongation-competent ribosome [16–18]. mRNAs possess regulatory elements that regulate the frequency of translation initiation, choice of the open reading frame (ORF), global and local




FIGURE 1: Eukaryotic ribosome synthesis. Eukaryotic ribosome synthesis is a complex process that comprises 5 steps, including transcription, processing, modification, assembly, and transport. (1) Transcription: RNA polymerase I transcribes rDNA into 47S pre-rRNA. RNA polymerase III transcribes 5S rRNA. snoRNAs are transcribed by RNA polymerase II or III from non-protein-encoding regions or mRNA introns. RNA polymerase II transcribes the mRNAs for ribosome proteins (RPs) and assembly factors (AFs). (2) Processing: 47S pre-rRNA is processed to 18S, 28S, and 5.8S rRNAs. (3) Modification: there are two primary kinds of modifications on rRNA that are mediated by snoRNAs: 2'-O-methylation (2'-O-Me) and pseudouridines ( $\Psi$ ). (4) Assembly: RPs and AFs are translated in the cytoplasm and shuttled to the nucleus for ribosome assembly. The pre-60S subunits comprise 28S, 5.8S, and 5S rRNA, and the pre-40S subunit includes an additional 18S rRNA. (5) Transport: the subunits are transported to the cytoplasm via the nuclear pore to be assembled as needed during translation.

rates of elongation, and protein folding [19]. Structured or excessively short 5' UTRs [20, 21] and upstream open reading frames (uORFs) [20, 22] negatively influence translation efficiency, while internal ribosome entry sites (IRESs) [23, 24], other regions of direct ribosomal recruitment [25, 26], and codon bias at the sites of initiation sites [27, 28] enhance initiation in response to ribosome shortage. The efficiency of elongation depends on codon usage, secondary structures in the mRNA, and ribosome density. Finally, translation terminates when the ribosome encounters a termination codon [19]. Thus, the cis-elements in mRNAs can be used in combinations to regulate the activity of ribosomes, thereby resulting in selective gene expression. This gives rise to ribosome heterogeneity that includes subsets of ribosomes with differential selectivity for mRNA subpools [2].

**1.2. Assembly of Ribosomes.** Ribosome synthesis is an energy-intensive process that requires complex machinery comprising numerous proteins and RNAs (Figure 1) [29]. Ribosomes are assembled from large and small subunits: large and small subunits predominantly function in peptide bond transfer and mRNA decoding, respectively [30]. There are four main

components of ribosome synthesis: ribosome proteins (RPs), assembly factors (AFs), ribosomal RNAs (rRNAs), and small nucleolar RNAs (snoRNAs) [1]. Ribosome precursors are synthesized in nucleoli whose internal structure comprises three characteristic regions: fiber center (FC), dense fiber component (DFC), and particle component. rRNAs are transcribed between FC and DFC. rRNAs and their binding proteins reside in the DFC. rRNAs are also cleaved, processed, and modified in the DFC. The ribosome precursor is assembled in the particle component [31]. In eukaryotic nucleoli, RNA polymerase I transcribes rDNA into 47S pre-rRNA that is spliced to form 5.8S, 28S, and 18S rRNA [32, 33]. In the eukaryotic nucleus, RNA polymerase III transcribes 5S rRNA that participates in the formation of the 60S subunit with 28S and 5.8S rRNA. The 40S subunit is composed of 18S rRNA and 33 RPs, while the 60S subunit comprises 5S, 5.8S, and 28S rRNA and 47 RPs.

rRNAs can be modified or processed by snoRNAs [34] that are transcribed by RNA polymerase II or III or arise from pre-mRNA introns. snoRNAs are found in the nucleus and provide a direct role in the post transcription of rRNA and mRNA [35]. snoRNAs interact with proteins to form

small nuclear ribonucleoproteins (snoRNPs) that direct rRNA processing and modification [36].

There are ~80 RPs [37], majority of which are cotranscribed with rRNA [38]. mRNAs for RPs are translated in the cytoplasm following which they are transported back to the nucleus to form the precursor of ribosomal subunits. To enable efficient protein translation, ribosome assembly also requires specific AFs [39]. Eukaryotes possess more than 500 AFs [40]. AFs are associated with rRNA at specific stages including rRNA processing and modification, thereby facilitating the binding of RP and influencing ribosome biogenesis [41]. AFs mainly consist of multiple enzymes and proteins with known protein or RNA-binding domains. Specific AFs such as FBL and BYSL are overexpressed in stem cells and maintain pluripotency by promoting ribosome biogenesis [42–44].

Differentiation of embryonic stem (ES) cells can be caused by a decrease in ribosomal abundance. Inhibition of protein synthesis influences numerous proteins with short half-lives. The expression of key proteins with short half-lives depends on multiple factors [45]. In human ES cells, the expression of the short-lived Nanog protein is erratic. The proteolysis of Nanog is mediated by the ubiquitin–proteasomal pathway [46]. Mouse embryonic stem cell (mESCs) can be treated with the transcription inhibitor 4EGI-1 to result in the rapid reduction of the protein levels of Nanog, Esrrb, and Tfcp2l1 and a steady time-dependent reduction in their mRNA levels [47]. Ribosome biogenesis is composed of five main steps involving transcription, processing, modification, assembly, and transport of ribosome precursors. Careful regulation of the multiple steps in ribosome biogenesis enables efficient translation and is critical for maintaining pluripotency.

**1.3. Ribosome-Induced Cellular Transdifferentiation.** Transdifferentiation involves the reprogramming of somatic cells into those of a different lineage without going through the intermediate proliferative pluripotent stem cell stage; it is a new method to generate functional cells [48–50]. *Mycobacterium leprae* transdifferentiates Schwann cells into pluripotent cells by downregulating differentiation markers (SOX10, Mpz, and p75) and upregulating genes associated with mesodermal development (Sox2, CD44, and CD43) [51]. *Helicobacter pylori* infection in intestinal epithelial cells promotes the expression of CDX1 [52]. CDX1 induces the expression of pluripotency factors KLF5 and SALL4, thereby transdifferentiating gastric epithelial cells into intestinal epithelial-like cell [52, 53]. Proteins from *Wolbachia pipientis*, especially W20, accelerate mammalian cell reprogramming [54]. Lactic acid bacteria (LAB) convert human dermal fibroblasts (HDFs) into pluripotent cells [55]. LAB-differentiated cell clusters have the potential to form three germ layer cells along with increasing the expression of the marker for pluripotency, Nanog [55]. Thus, bacteria promote host cell reprogramming, but the mechanisms involved remain to be investigated. To understand LAB-induced transdifferentiation of HDFs, LAB lysates were used to treat trypsinized HDFs; the protein fraction of size > 100 kDa obtained from ultrafiltered lysates was found to induce cell cluster forma-

tion [10]. Owing to the size of the fraction, the “transdifferentiation factor” was speculated to be the ribosome. Purified ribosomes obtained by ultracentrifugation promoted HDF transdifferentiation. These ribosome-induced cell clusters can enhance the expression of pluripotency factors and give rise to endodermal, mesodermal, and ectodermal cells, but they could not form teratomas and chimeras [10]. Ribosome-induced cell clusters need to be induced with trypsin [56]. Since the diameter of a ribosome is ~20 nm [57], it can undergo nucleocytoplasmic shuttling and internalized by other cells via endocytosis by endosomal vesicles that are ~10 μm in size [58]. The characteristics of this ribosome that promote transdifferentiation and express stem cell markers remain to be understood fully.

**1.4. rRNA Transcription Efficiency Determines the Fate of Stem Cells.** The nucleus of ES cells quickly adapts to increases in cellular proliferation that requires rapid transcription of rRNAs [59, 60]. To promote the initiation of transcription, RNA polymerase I specifically binds to the promoter region of rDNA via transcription factors, such as upstream binding factor (UBF) and promoter selectivity factor (SL1/TIF-IB) [61]. The efficiency of rRNA transcription determines the speed of ribosome biosynthesis and assembly. Stem cells heavily transcribe rRNAs, but their levels decrease as cells differentiate [32]. The expression of c-Myc, an important stem cell marker, decreases during differentiation [62]. A reduction in the levels of RNA polymerase-associated factors downregulates rRNA synthesis [63], thereby inducing cell differentiation [64]. Downregulation of rRNA correlates with an increase in the levels of lineage-specific factors that are responsible for differentiation into specific cell types (e.g., MyoD and myogenin during myogenesis, Runx2 during osteogenesis, and C/EBP-β, C/EBP-δ, and C/EBP-α during adipogenesis); these factors hinder rRNA transcription by interacting with UBF or rDNA promoters [65]. An *ex vivo* experiment demonstrated that actinomycin D-mediated inhibition of rRNA transcription induces the differentiation of mouse hematopoietic stem cells (HSCs). Thus, it is generally accepted that a decrease in rRNA transcription correlates with cellular differentiation.

In eukaryotes, 75% of rRNAs are transcribed by RNA polymerase I [1]. This enzyme complex comprises Udd, TAF1B, and a TAF1C-like factor in *Drosophila*. Increased transcription by RNA polymerase I inhibits cell differentiation, while inhibition of RNA polymerase I-mediated transcription limits ribosome biogenesis and promotes cellular differentiation [66]. FBL methylates a glutamine residue in histone H2A and stimulates RNA polymerase I binding on rDNA gene promoters [67].

A recent study has shown that 17 pluripotency-associated factors bind rDNA loci in mESCs [32]. Moreover, silencing of rDNA genes and downregulated ribosome biogenesis are associated with stem cell ageing in murine HSCs [68]. In general, stem cells have higher rRNA transcription efficiency than the daughter cells and rRNA synthesis is downregulated by phenotype-specific transcription factors during differentiation. rDNA transcription is quantitatively regulated in stem cells and the rate of rDNA transcription influences cell fate.

Beyond rDNA transcription: many factors at all steps of the process appear to play stem cell-specific roles.

**1.5. rRNA Processing and Stem Cells.** rRNA processing is an evolutionarily conserved phenomenon that is essential for ribosome assembly. Ribosome assembly and pre-rRNA processing are closely linked, and the primary 47S transcript is cleaved to the 20S and 32S intermediates that are processed to the mature 18S and 5.8/28S rRNAs (components of the 40S and 60S ribosomal subunits, respectively). Stem cell AFs promote rRNA processing to improve the efficiency of ribosome synthesis. Small subunit processome (SSUP) is a pre-18S processing complex composed of snoRNA U3 and 54 proteins encoded by six genes (Krr1, Ddx47, Ddx52, Nol6, Pdcd11, and Rrp7a) in mESCs [4]. These SSUP genes are overexpressed in stem cells but downregulated during embryoid body formation. Depleting cells of the SSUP reduces Nanog expression, while knocking out SSUP genes hinder cellular reprogramming. Krr1, a conserved yeast homolog of SSUP [45], promotes the cleavage of 18S rRNA at sites A0, A1, and A2 to generate the 40S subunit [69]. SSUP stimulates pluripotency by enhancing translation. ES cells exhibit an upregulation in the subunits of SSUP, thereby enhancing the rate of translation and regulating pluripotency.

*Lrrc34* (leucine-rich repeat-containing 34) is another gene that is robustly expressed in mESCs and is downregulated during differentiation [70]. *Lrrc34* is a nucleolar protein that interacts with nucleophosmin and nucleolin regulate pluripotency-related genes, such as OCT4, and is important in rRNA processing and ribosome formation [71]. Urb2, another nucleolar protein, plays a role in 27S pre-rRNA processing and 60S subunit biogenesis [72]. Moreover, mutations in Urb2 impair HSC development by disrupting the biogenesis of ribosomal subunits and rRNAs in zebrafish [11, 72].

Nucleostemin is overexpressed in proliferating cells, such as central nervous system stem cells, ES cells, and cancer cell lines, and downregulated during differentiation. It contains an N-terminal basic domain that is involved in nucleolar localization and two GTP-binding motifs that regulate its transport between the nucleolus and nucleoplasm [73, 74]. Nucleostemin regulates cell proliferation via p53 signaling and is involved in ribosomal biogenesis, especially pre-rRNA processing. It is a large protein complex (>700 kDa) comprising five ribosomal subunits (RPS6, RPS8, RPS24, RPL13, and RPL14), three nucleolar proteins (DDX21, Pes1, and EBP2), and a translation initiation factor (eIF2B1) [75]. DDX21 is a DExD/H box protein that uses energy from ATP hydrolysis to unwind RNA or disrupt RNA-protein complexes that could alter RNA [76]. It stabilizes 28S rRNA, promotes the conversion of the 20S pre-rRNA into 18S RNA in *Xenopus*, and processes of 18S and 28S rRNAs in humans [77]. Pes1 is also involved in processing the 12, 36, and 32S pre-rRNAs in mammals, thereby promoting the biogenesis of the 60S ribosomal subunit [78]. EBP2 interacts with ribosomal proteins L36, L34, and L8; L36 is important for processing 27SA2, 27SA3, and 27SBL pre-rRNAs [79]. Furthermore, nucleostemin and 60S subunits can be found in the same fraction following sucrose gradient centrifugation,

indicating the involvement of nucleostemin in ribosome synthesis [75]. In summary, the interactions between DDX21, Pes1, EBP2, and nucleostemin enhance pre-rRNA processing to promote 60S ribosomal subunit synthesis and improve the efficiency of translation.

Bystin-like (BYSL) is detected in abundance in rapidly proliferating embryo and cancer cells and is evolutionarily conserved across eukaryotes, especially the C-terminus that regulates its nuclear localization [80–83]. Knocking out BYSL inhibits the synthesis of 18S rRNA and enables the accumulation of 20S rRNA precursors without affecting 28S rRNA. Moreover, there is a decrease in the cytoplasmic content of the 40S subunit, suggesting the role of Bysl in the export of the 40S subunit [33]. Bysl is also a key regulator of c-Myc and is overexpressed in stem and cancer cells [84, 85]. Enp1 is the yeast ortholog of Bysl that is predominantly localized to the nucleolus. Similar to Krr1, Enp1 functions in 18S rRNA processing and cleavage of the 35S pre-rRNA at sites A0, A1, and A2 [86]. Enp1 has been observed to coimmunoprecipitate with a cohort of proteins, including Nop1 (the yeast ortholog of FBL) [87]. Enp1 and Nop1 interact with snoRNAs U3 and U14 and stimulate rRNA processing.

**1.6. Specific rRNA Modifications in Stem Cells.** rRNA modifications change according to different stimuli, diseases, and development, and this results in ribosome heterogeneity, thereby differentially regulating gene expression [34]. Eukaryotic rRNAs possess 91 pseudouridines ( $\Psi$ ), 105 sugars containing 2'-O-methylation (2'-O-Me), and 10 methylated bases [88]. Modifications are primarily found in the functional regions of the ribosome and are induced by snoRNPs wherein snoRNAs complementary to specific rRNA sequences determine the methylation site [89, 90]. snoRNAs can be divided into C/D or H/ACA box-containing snoRNAs [91]. C/D box snoRNAs predominantly undergo 2'-O-Me modification, while H/ACA box snoRNAs undergo substitution with  $\Psi$  [92]. rRNA modification alters the secondary and tertiary structure of ribosomes that is important for ribosome biogenesis and function [93]. Differential modification of particular rRNA sites results in ribosome heterogeneity.

Fragile X mental retardation protein (FMRP) is an RNA-binding protein that is important for neuronal development and differentiation. In animal and human stem cells, FMRP maintains pluripotency, regulates cell fate, and determines the speed of generating neuronal lineage-committed cells [94–97]. FMRP has been shown to function predominantly in the cytoplasm; however, recent evidence has demonstrated its role in the nucleus [98, 99]. In the nuclei of human embryonic stem cells, FMRP directly interacts with C/D box snoRNAs and results in the 2'-O-Me modification of rRNA, thereby causing ribosome heterogeneity by affecting rRNA folding and ribosomal assembly [100, 101]. In the cytoplasm, FMRP identifies 2'-O-Me-modified ribosomes to enable specific translation of its target mRNAs [101, 102]. FMRP promotes the expression of genes involved in stem cell intracellular pathways, such as mTOR, PI3K, ERK, and Gsk3 $\beta$  [103–106].

Fibrillarlin is a protein that is involved in proliferation [107], cancer [108], and stem cell differentiation [43].

Fibrillarin is enriched in the DFC region of the nucleolus and contains an N-terminal domain rich in glycine and arginine residues (namely the GAR domain), a central RNA-binding domain comprising an RNP-2-like consensus sequence, and a highly conserved C-terminal helical domain that may act as methyltransferases [109, 110]. The human GAR domain enables fibrillarin-interacting pre-rRNAs to process nascent 47S pre-rRNAs and demarcate the DFC region. As a part of C/D box snoRNPs, FBL catalyzes the 2'-O-Me of rRNAs to regulate ribosome biogenesis and translation [111, 112]. Thus, fibrillarin functions in pre-rRNA processing and modification, thereby regulating ribosomal biogenesis. It can also enhance the activity of RNA polymerase I. Nop1, the yeast homolog of fibrillarin, also processes pre-rRNAs, especially 18S rRNA. Fibrillarin has been reported to be overexpressed in mouse embryonic stem cells and maintains pluripotency state even in the absence of LIF [43]. During stem cell differentiation and neurogenesis, fibrillarin is downregulated and may affect the 2'-O-Me modification of rRNAs to regulate ribosome biogenesis with modified translational specificity such that IRES-containing mRNAs (e.g., *cMYC*, *FGF1*, and *VEGFA*) are preferentially translated instead of 5'-capped transcripts [43, 107, 108].

**1.7. RP Heterogeneity in Stem Cells.** Differences in RP composition and isoform lead to ribosome heterogeneity [113] that enables the recognition of sequence-specific elements or structures in mRNAs and selective expression [2, 114, 115]. Various RPs express to different extents in different tissues of the developing mouse embryo [116].

Quantitative mass spectrometry was used to measure the RP abundance and identify heterogeneous compositions of translationally active ribosomes in mESCs [2]. Ribosomes containing RPS25 or RPL10A translate specific transcript subpools, including mRNAs encoding key components in metabolism, the cell cycle process, and development, while the depletion of RPL10A does not affect the overall polysome profiles but reduces translation efficiencies of mRNAs associated with metabolism [2]. The heterogeneous RPs identified by SRM are located on the surface of the ribosome in important functional regions including the mRNA exit tunnel and the L1 stalk and thus directly interacts with mRNAs [117, 118]. RPL10A directly interacts with the IRES and engages the 80S ribosome independent of some or all initiation factors to achieve translational regulation of mRNAs, highlighting the importance of cis-regulatory elements in selective mRNA translation [2, 119, 120].

Diamond-Blackfan anemia is a special hematological disease. Patients present with a decrease in the population of erythroid precursors and progenitors in the bone marrow that is caused by heterozygous loss-of-function mutations in one of 18 different RP genes (e.g., RPL11, RPS19), thereby resulting in RP haploinsufficiency [121, 122]. Knockdown of RPL11 or RPS19 reduces IRES-mediated translation, especially of Bag1 that protects GATA1 from caspase-3-mediated cleavage during terminal erythroid differentiation [123–125]. RP mutations reduce the key lineage-determining hematopoietic transcription factor GATA1 mRNA in Diamond-Blackfan anemia [125].

Mutations in RPL21 are linked to stem cell-specific defects, such as loss of body hair [126]. RPL38 mutant embryos show no change in global protein synthesis but selectively affect the translation of a subset of Homeobox mRNAs [116].

Collectively, these findings suggest that RPs are regulated to confer a new layer of specificity in the control of gene expression, mammalian development, and stem cell biology.

**1.8. AFs Interact with RPs to Regulate Stem Cell Function.** RP synthesis is closely linked to other biological processes [127]. RPs are translated in the cytoplasm by preexisting ribosomes following which they enter the nucleoli and bind to rRNA to form ribosomes. RPs may play selective roles in eukaryotic ribosomes during cellular homeostasis and development [114]. Some AFs directly interact with and stabilize RPs, while others associate with DNA to stimulate transcription. UBA52 encodes a fusion protein of ubiquitin and RPL40 that is important for embryonic development. The RPL40 cleaved from UBA52 is important in protein biogenesis and forms a ribosomal complex with ubiquitin cleaved from UBA52. Efficient protein synthesis requires the cleavage of RPL40 from the fusion protein [128].

Bmi1 is a member of the polycomb group of proteins that bind to the promoter of target genes and induce epigenetic modifications in the chromatin to regulate cancer and stem cell biology [129–131]. Bmi1 affects the proliferation and differentiation of HSCs as well as other stem cells, such as mesenchymal stem cells and neural stem cells [132, 133]. In K562 cells, Bmi1 binds to the promoter of ribosomal genes, such as *RPL5*, *RPL1*, *RPL23*, *RPS14*, and *RPS19*; thus, a loss in this interaction downregulates ribosomal proteins and results in impaired ribosome biogenesis, thereby reducing global translation efficiency [134, 135]. Bmi1 promotes the transcription of RPs by recruiting active histone marks including H3K9ac and H3K4me3.

Runx1, another transcription factor, binds to the promoters of RP-encoding genes and rDNA repeats to regulate the transcription of rDNA and ribosomal biogenesis in HSPCs [65, 136]. Runx1 forms the core ribosomal promoter element with RUNX1, GATA2, and FLI1 that affects ribosomal biogenesis in conjunction with cooperative hematopoietic transcription factors [137, 138]. Runx1 is regulated by the global regulator of ribosome biogenesis, Myc [139]. Moreover, Bmi1 directly interacts with RUNX1 to recruit polycomb repressor complex 1 to regulate ribosome biogenesis and assembly [140].

The phosphatidylinositol-3-kinase (PI3K)/Akt and mammalian target of rapamycin (mTOR) signaling pathways (PI3K/Akt/mTOR) are pivotal for cell growth and survival [141–144]. Cells can be reprogrammed by activating IGF1/AKT/mTOR signaling and increasing the translation of RPs in cells depleted of MeCP2 (Figure 2) [145]. mTOR phosphorylates downstream effectors, including S6 kinase (S6K) [146] and eukaryotic initiation factor 4E (eIF4E) binding protein 1 (4E-BP1) [147, 148]. eIF4E inhibits translation, while mTOR-phosphorylated eIF4E relieves translational suppression to promote cap-dependent translation [148]. The phosphorylation of S6K promotes the biogenesis of




FIGURE 2: PI3K/AKT/mTORC1 signaling involved in translation and pluripotency. PI3K is activated by cytokines, such as LIF, Wnt, and growth factor receptors, to induce cell proliferation and regulate mTOR signaling to maintain pluripotency. This primarily involves the mTORC1 complex that phosphorylates S6K and 4EBP-1. Phosphorylated 4EBP-1 relieves suppressed translation by stimulating cap-dependent translation; phosphorylated S6K increases the levels of ribosomal protein S6 that is important in the biogenesis of 40S subunits. This helps maintain stem cell pluripotency by enhancing ribosome biogenesis to promote the translation of specific stem cell genes.

RpS6 (component of the 40S subunit) and translation [149, 150]. mTOR is important for the development of ES cells and can be regulated by PI3K signaling involved in ES cell pluripotency [151–153].

**1.9. Ribosome Assembly and Transport in Stem Cells.** PDCD2 is a conserved protein in eukaryotes that is present in mouse ES cells and other rapidly proliferating cells, such as cancer cells, and detected in abundance (if at all) in differentiated or slow-growing cells [154–157]. Zfrp8, the homolog of PDCD2 in *Drosophila*, functions in the maintenance of HSCs [158]. PDCD2 is a member of TYPP domain-containing proteins (TSR4, YwqG, PDCD2L, and PDCD2), among which TSR4 regulates rRNA processing and ribosome maturation [159]. Zfrp8/PDCD2 directly interacts with the 40S ribosomal subunit via RpS2, thereby regulating the cytoplasmic levels of RpS2 and stability of the 40S subunit [160]. The 40S subunit consists of more than 30 RPs that bind to numerous non-RPs to regulate translation, subunit assembly, and nucleocytoplasmic transport [161, 162]. Thus, Zfrp8/PDCD2 plays a key role in translation; however, it is not essential during general translation [160]. Zfrp8/PDCD2 can recruit different RNA-binding proteins, such as FMRP/Fmr1 and NUFIP1/Nufip (nuclear FMRP-interacting protein), form mRNA-RNP complexes that bind specifically to the 40S subunit, and spatiotemporally regulate target gene expression [163–165]. Zfrp8/PDCD2 also regulates the translation of protein-coding genes by promoting nuclear export of the mRNAs [160]. Thus, Zfrp8/PDCD2 is important in ribosome

assembly and regulates the transport of specific mRNAs to maintain properly functioning stem cells.

## 2. Conclusions

Ribosomes are tools that are important for translation in different kinds of cells. However, recent research has shown that it exists in heterogeneous forms to differentially regulate gene expression [2]. Ribosome biogenesis is a very complex process. Although the basic steps of ribosome synthesis are conserved [166], there are various factors that can regulate the different processes [167] to modulate the translation efficiency of specific genes. Most of these factors are highly expressed in stem cells; knockout or mutation affects stem cell function and leads to cell death. Ribosome heterogeneity is when ribosomes have different composition, such as rRNAs, RPs, and AFs, and allows the selective translation of mRNAs to generate the appropriate types and amounts of proteins needed to regulate cellular function to the environment. Specific features in mRNAs, such as cis-elements, are recognized by specialized ribosomes, thereby enabling selective translation [2]. What is more, mRNA recognition and translation by the ribosome are based on combinatorial sets of RNA–RP interactions; thus, ribosome heterogeneity and its role in translational control may be mainly determined by RP composition and modification [115]. We know that there is a long way to go to decipher the heterogeneity ribosome, and recently, research discovered that

stem cells and differentiated cells express different subsets of tRNAs [168, 169].

Stem cells differentiate into lineage-committed cells that proliferate to form specific tissues, organs, and systems in our body, thereby highlighting their importance as ideal sources for repair of damaged cells and tissues. Owing to the limited abundance of stem cells, Yamanaka and colleagues expressed four specific genes (*OCT4*, *KLF4*, *SOX2*, and *CMYC*; OSKM) to reprogram differentiated cells into induced pluripotent stem cells [170]. However, since reprogramming is an inefficient process, there is ongoing research on the identification of factors that accelerate reprogramming [171, 172]. Numerous studies have shown that the presence of long noncoding RNAs (lncRNAs) promote the maintenance of stem cell function [173]. lncRNAs, such as Peblr20 and SNHG14, significantly improve reprogramming efficiency [174, 175]. This review focuses on the diversity of ribosomes associated with the translational control of stem gene expression and identification of specific recognition elements in the mRNAs associated with stemness. AFs in stem cells improve the efficiency of ribosome biogenesis and promote the translation of stem cell-related genes. Thus, using these AFs with the factors involved in reprogramming (lncRNAs, proteins, etc.) will promote ribosome synthesis and improve reprogramming efficiency. However, further research is required on the mechanisms by which ribosomes specifically regulate the expression of selective stem cell-related genes. Addressing this will pave way for a new direction in stem cell research that will help stimulate stem cell reprogramming and promote the clinical application of stem cells.

## Data Availability

No data were used to support this study.

## Conflicts of Interest

The authors declare that they have no conflict of interest.

## Acknowledgments

We would like to thank Editage (<http://www.editage.cn>) for English language editing. Publication of this review was supported by the National Natural Science Foundation of China (grant numbers 81372835 and 81670143) and National Key Research and Development Program of China (grant number 2018YFA0106902).

## References

- [1] D. L. J. Lafontaine, "Noncoding RNAs in eukaryotic ribosome biogenesis and function," *Nature Structural & Molecular Biology*, vol. 22, no. 1, pp. 11–19, 2015.
- [2] Z. Shi, K. Fujii, K. M. Kovary et al., "Heterogeneous ribosomes preferentially translate distinct subpools of mRNAs genome-wide," *Molecular Cell*, vol. 67, no. 1, pp. 71–83.e7, 2017.
- [3] V. P. Mauro and G. M. Edelman, "The ribosome filter redux," *Cell Cycle*, vol. 6, no. 18, pp. 2246–2251, 2014.
- [4] K. T. You, J. Park, and V. N. Kim, "Role of the small subunit processome in the maintenance of pluripotent stem cells," *Genes & Development*, vol. 29, no. 19, pp. 2004–2009, 2015.
- [5] H. J. Lee, R. Gutierrez-Garcia, and D. Vilchez, "Embryonic stem cells: a novel paradigm to study proteostasis?," *The FEBS Journal*, vol. 284, no. 3, pp. 391–398, 2017.
- [6] A. Noormohammadi, A. Khodakarami, R. Gutierrez-Garcia et al., "Somatic increase of CCT8 mimics proteostasis of human pluripotent stem cells and extends *C. elegans* lifespan," *Nature Communications*, vol. 7, no. 1, article 13649, 2016.
- [7] L. García-Prat, P. Sousa-Victor, and P. Muñoz-Cánoves, "Proteostatic and metabolic control of stemness," *Cell Stem Cell*, vol. 20, no. 5, pp. 593–608, 2017.
- [8] A. Noormohammadi, G. Calculli, R. Gutierrez-Garcia, A. Khodakarami, S. Koyuncu, and D. Vilchez, "Mechanisms of protein homeostasis (proteostasis) maintain stem cell identity in mammalian pluripotent stem cells," *Cellular and Molecular Life Sciences*, vol. 75, no. 2, pp. 275–290, 2018.
- [9] L. Jarzembowski, M. le Bouteiller, S. Coqueran et al., "Mouse adult hematopoietic stem cells actively synthesize ribosomal RNA," *RNA*, vol. 24, no. 12, pp. 1803–1812, 2018.
- [10] N. Ito, K. Katoh, H. Kushige et al., "Ribosome incorporation into somatic cells promotes lineage transdifferentiation towards multipotency," *Scientific Reports*, vol. 8, no. 1, p. 1634, 2018.
- [11] P. Cai, X. Mao, J. Zhao, and L. Luo, "Ribosome biogenesis protein Urb2 regulates hematopoietic stem cells development via P53 pathway in zebrafish," *Biochemical and Biophysical Research Communications*, vol. 497, no. 2, pp. 776–782, 2018.
- [12] A. Bastide and A. David, "The ribosome, (slow) beating heart of cancer (stem) cell," *Oncogene*, vol. 7, no. 4, p. 34, 2018.
- [13] N. E. Shirokikh, S. K. Archer, T. H. Beilharz, D. Powell, and T. Preiss, "Translation complex profile sequencing to study the *in vivo* dynamics of mRNA-ribosome interactions during translation initiation, elongation and termination," *Nature Protocols*, vol. 12, no. 4, pp. 697–731, 2017.
- [14] L. F. Lareau, D. H. Hite, G. J. Hogan, and P. O. Brown, "Distinct stages of the translation elongation cycle revealed by sequencing ribosome-protected mRNA fragments," *eLife*, vol. 3, article e01257, 2014.
- [15] P. Shah, Y. Ding, M. Niemczyk, G. Kudla, and J. B. Plotkin, "Rate-limiting steps in yeast protein translation," *Cell*, vol. 153, no. 7, pp. 1589–1601, 2013.
- [16] A. G. Hinnebusch, "The scanning mechanism of eukaryotic translation initiation," *Annual Review of Biochemistry*, vol. 83, no. 1, pp. 779–812, 2014.
- [17] A. Marintchev, "Roles of helicases in translation initiation: a mechanistic view," *Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms*, vol. 1829, no. 8, pp. 799–809, 2013.
- [18] W. C. Merrick, "Eukaryotic protein synthesis: still a mystery," *The Journal of Biological Chemistry*, vol. 285, no. 28, pp. 21197–21201, 2010.
- [19] M. V. Rodnina, "The ribosome in action: tuning of translational efficiency and protein folding," *Protein Science*, vol. 25, no. 8, pp. 1390–1406, 2016.
- [20] M. Kozak, "Regulation of translation via mRNA structure in prokaryotes and eukaryotes," *Gene*, vol. 361, pp. 13–37, 2005.
- [21] T. V. Pestova and V. G. Kolupaeva, "The roles of individual eukaryotic translation initiation factors in ribosomal scanning

- and initiation codon selection,” *Genes & Development*, vol. 16, no. 22, pp. 2906–2922, 2002.
- [22] C. Vilela and J. E. G. McCarthy, “Regulation of fungal gene expression via short open reading frames in the mRNA 5' untranslated region,” *Molecular Microbiology*, vol. 49, no. 4, pp. 859–867, 2003.
- [23] G. Lozano and E. Martínez-Salas, “Structural insights into viral IRES-dependent translation mechanisms,” *Current Opinion in Virology*, vol. 12, pp. 113–120, 2015.
- [24] A. A. Komar, B. Mazumder, and W. C. Merrick, “A new framework for understanding IRES-mediated translation,” *Gene*, vol. 502, no. 2, pp. 75–86, 2012.
- [25] W. V. Gilbert, K. Zhou, T. K. Butler, and J. A. Doudna, “Cap-independent translation is required for starvation-induced differentiation in yeast,” *Science*, vol. 317, no. 5842, pp. 1224–1227, 2007.
- [26] N. E. Shirokikh and A. S. Spirin, “Poly(A) leader of eukaryotic mRNA bypasses the dependence of translation on initiation factors,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 31, pp. 10738–10743, 2008.
- [27] M. Kozak, “Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes,” *Cell*, vol. 44, no. 2, pp. 283–292, 1986.
- [28] M. Kozak, “Point mutations close to the AUG initiator codon affect the efficiency of translation of rat preproinsulin *in vivo*,” *Nature*, vol. 308, no. 5956, pp. 241–246, 1984.
- [29] H. Lempiäinen and D. Shore, “Growth control and ribosome biogenesis,” *Current Opinion in Cell Biology*, vol. 21, no. 6, pp. 855–863, 2009.
- [30] T. A. Steitz, “A structural understanding of the dynamic ribosome machine,” *Nature Reviews Molecular Cell Biology*, vol. 9, no. 3, pp. 242–253, 2008.
- [31] S. A. Pirogov, V. A. Gvozdev, and M. S. Klenov, “Long non-coding RNAs and stress response in the nucleolus,” *Cell*, vol. 8, no. 7, p. 668, 2019.
- [32] A. Brombin, J. S. Joly, and F. Jamen, “New tricks for an old dog: ribosome biogenesis contributes to stem cell homeostasis,” *Current Opinion in Genetics & Development*, vol. 34, pp. 61–70, 2015.
- [33] K. Adachi, C. Soeta-Saneyoshi, H. Sagara, and Y. Iwakura, “Crucial role of Bysl in mammalian preimplantation development as an integral factor for 40S ribosome biogenesis,” *Molecular and Cellular Biology*, vol. 27, no. 6, pp. 2202–2214, 2007.
- [34] K. E. Sloan, A. S. Warda, S. Sharma, K. D. Entian, D. L. J. Lafontaine, and M. T. Bohnsack, “Tuning the ribosome: the influence of rRNA modification on eukaryotic ribosome biogenesis and function,” *RNA Biology*, vol. 14, no. 9, pp. 1138–1152, 2017.
- [35] G. T. Williams and F. Farzaneh, “Are snoRNAs and snoRNA host genes new players in cancer?,” *Nature Reviews Cancer*, vol. 12, no. 2, pp. 84–88, 2012.
- [36] A. K. Henras, C. Dez, and Y. Henry, “RNA structure and function in C/D and H/ACA s(no)RNPs,” *Current Opinion in Structural Biology*, vol. 14, no. 3, pp. 335–343, 2004.
- [37] W. Wang, S. Nag, X. Zhang et al., “Ribosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implications,” *Medicinal Research Reviews*, vol. 35, no. 2, pp. 225–285, 2015.
- [38] J. de la Cruz, K. Karbstein, and J. L. Woolford Jr., “Functions of ribosomal proteins in assembly of eukaryotic ribosomes *in vivo*,” *Annual Review of Biochemistry*, vol. 84, no. 1, pp. 93–129, 2015.
- [39] D. Kressler, E. Hurt, and J. Bassler, “Driving ribosome assembly,” *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*, vol. 1803, no. 6, pp. 673–683, 2010.
- [40] Tafforeau L., Zorbas C., Langhendries J. -L. et al., “The complexity of human ribosome biogenesis revealed by systematic nucleolar screening of pre-rRNA processing factors,” *Molecular Cell*, vol. 51, no. 4, pp. 539–551, 2013.
- [41] B. S. Strunk and K. Karbstein, “Powering through ribosome assembly,” *RNA*, vol. 15, no. 12, pp. 2083–2104, 2009.
- [42] H. Wang, W. Xiao, Q. Zhou et al., “Bystin-like protein is upregulated in hepatocellular carcinoma and required for nucleologenesis in cancer cell proliferation,” *Cell Research*, vol. 19, no. 10, pp. 1150–1164, 2009.
- [43] K. Watanabe-Susaki, H. Takada, K. Enomoto et al., “Biosynthesis of ribosomal RNA in nucleoli regulates pluripotency and differentiation ability of pluripotent stem cells,” *Stem Cells*, vol. 32, no. 12, pp. 3099–3111, 2014.
- [44] K. Newton, E. Petfalski, D. Tollervey, and J. F. Cáceres, “Fibrillarin is essential for early development and required for accumulation of an intron-encoded small nucleolar RNA in the mouse,” *Molecular and Cellular Biology*, vol. 23, no. 23, pp. 8519–8527, 2003.
- [45] S. Zheng, P. Lan, X. Liu, and K. Ye, “Interaction between ribosome assembly factors Krr1 and Faf1 is essential for formation of small ribosomal subunit in yeast,” *The Journal of Biological Chemistry*, vol. 289, no. 33, pp. 22692–22703, 2014.
- [46] S. Ramakrishna, B. Suresh, K.-H. Lim et al., “PEST motif sequence regulating human NANOG for proteasomal degradation,” *Stem Cells and Development*, vol. 20, no. 9, pp. 1511–1519, 2011.
- [47] N. J. Moerke, H. Aktas, H. Chen et al., “Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G,” *Cell*, vol. 128, no. 2, pp. 257–267, 2007.
- [48] C. Mollinari, J. Zhao, L. Lupacchini, E. Garaci, D. Merlo, and G. Pei, “Transdifferentiation: a new promise for neurodegenerative diseases,” *Cell Death & Disease*, vol. 9, no. 8, p. 830, 2018.
- [49] X. Xie, Y. Fu, and J. Liu, “Chemical reprogramming and transdifferentiation,” *Current Opinion in Genetics & Development*, vol. 46, pp. 104–113, 2017.
- [50] S. M. Chambers and L. Studer, “Cell fate plug and play: direct reprogramming and induced pluripotency,” *Cell*, vol. 145, no. 6, pp. 827–830, 2011.
- [51] T. Masaki, J. Qu, J. Cholewa-Waclaw, K. Burr, R. Raaum, and A. Rambukkana, “Reprogramming adult Schwann cells to stem cell-like cells by leprosy bacilli promotes dissemination of infection,” *Cell*, vol. 152, no. 1–2, pp. 51–67, 2013.
- [52] N. Ito and K. Ohta, “Reprogramming of human somatic cells by bacteria,” *Development, Growth & Differentiation*, vol. 57, no. 4, pp. 305–312, 2015.
- [53] Y. Fujii, K. Yoshihashi, H. Suzuki et al., “CDX1 confers intestinal phenotype on gastric epithelial cells via induction of stemness-associated reprogramming factors SALL4 and KLF5,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 109, no. 50, pp. 20584–20589, 2012.



- [54] T. Ikeda, I. Uchiyama, M. Iwasaki et al., "Artificial acceleration of mammalian cell reprogramming by bacterial proteins," *Genes to Cells*, vol. 22, no. 10, pp. 918–928, 2017.
- [55] K. Ohta, R. Kawano, and N. Ito, "Lactic acid bacteria convert human fibroblasts to multipotent cells," *PLoS One*, vol. 7, no. 12, article e51866, 2012.
- [56] M. W. Sherwood, I. A. Prior, S. G. Voronina et al., "Activation of trypsinogen in large endocytic vacuoles of pancreatic acinar cells," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 13, pp. 5674–5679, 2007.
- [57] H. Stark, F. Mueller, E. V. Orlova et al., "The 70S *Escherichia coli* ribosome at 23 Å resolution: fitting the ribosomal RNA," *Structure*, vol. 3, no. 8, pp. 815–821, 1995.
- [58] M. Kaksonen and A. Roux, "Mechanisms of clathrin-mediated endocytosis," *Nature Reviews Molecular Cell Biology*, vol. 19, no. 5, pp. 313–326, 2018.
- [59] E. Meshorer, D. Yellajoshula, E. George, P. J. Scambler, D. T. Brown, and T. Misteli, "Hyperdynamic plasticity of chromatin proteins in pluripotent embryonic stem cells," *Developmental Cell*, vol. 10, no. 1, pp. 105–116, 2006.
- [60] K. Nakamoto, A. Ito, K. Watabe et al., "Increased expression of a nucleolar Nop5/Sik family member in metastatic melanoma cells: evidence for its role in nucleolar sizing and function," *The American Journal of Pathology*, vol. 159, no. 4, pp. 1363–1374, 2001.
- [61] I. Grummt, "Life on a planet of its own: regulation of RNA polymerase I transcription in the nucleolus," *Genes & Development*, vol. 17, no. 14, pp. 1691–1702, 2003.
- [62] G. Poortinga, K. M. Hannan, H. Snelling et al., "MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation," *The EMBO Journal*, vol. 23, no. 16, pp. 3325–3335, 2004.
- [63] G. Poortinga, M. Wall, E. Sanij et al., "c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation," *Nucleic Acids Research*, vol. 39, no. 8, pp. 3267–3281, 2011.
- [64] Y. Hayashi, T. Kuroda, H. Kishimoto, C. Wang, A. Iwama, and K. Kimura, "Downregulation of rRNA transcription triggers cell differentiation," *PLoS One*, vol. 9, no. 5, article e98586, 2014.
- [65] S. A. Ali, S. K. Zaidi, C. S. Dacwag et al., "Phenotypic transcription factors epigenetically mediate cell growth control," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 18, pp. 6632–6637, 2008.
- [66] Q. Zhang, N. A. Shalaby, and M. Buszczak, "Changes in rRNA transcription influence proliferation and cell fate within a stem cell lineage," *Science*, vol. 343, no. 6168, pp. 298–301, 2014.
- [67] P. Tessarz, H. Santos-Rosa, S. C. Robson et al., "Glutamine methylation in histone H2A is an RNA-polymerase-I-dedicated modification," *Nature*, vol. 505, no. 7484, pp. 564–568, 2014.
- [68] J. Flach, S. T. Bakker, M. Mohrin et al., "Replication stress is a potent driver of functional decline in ageing haematopoietic stem cells," *Nature*, vol. 512, no. 7513, pp. 198–202, 2014.
- [69] R. Gromadka and J. Rytka, "The KRR1 gene encodes a protein required for 18S rRNA synthesis and 40S ribosomal subunit assembly in *Saccharomyces cerevisiae*," *Acta Biochimica Polonica*, vol. 47, no. 4, pp. 993–1005, 2000.
- [70] S. Meyer, J. Nolte, L. Opitz, G. Salinas-Riester, and W. Engel, "Pluripotent embryonic stem cells and multipotent adult germline stem cells reveal similar transcriptomes including pluripotency-related genes," *Molecular Human Reproduction*, vol. 16, no. 11, pp. 846–855, 2010.
- [71] S. Lührig, I. Siamishi, M. Tesmer-Wolf, U. Zechner, W. Engel, and J. Nolte, "Lrrc34, a novel nucleolar protein, interacts with npm1 and NCL and has an impact on pluripotent stem cells," *Stem Cells and Development*, vol. 23, no. 23, pp. 2862–2874, 2014.
- [72] I. V. Rosado, C. Dez, S. Lebaron, M. Caizergues-Ferrer, Y. Henry, and J. de la Cruz, "Characterization of *Saccharomyces cerevisiae* Npa2p (Urb2p) reveals a low-molecular-mass complex containing Dbp6p, Npa1p (Urb1p), Nop8p, and Rsa3p involved in early steps of 60S ribosomal subunit biogenesis," *Molecular and Cellular Biology*, vol. 27, no. 4, pp. 1207–1221, 2007.
- [73] R. Y. L. Tsai and R. D. G. McKay, "A multistep, GTP-driven mechanism controlling the dynamic cycling of nucleostemin," *The Journal of Cell Biology*, vol. 168, no. 2, pp. 179–184, 2005.
- [74] R. Y. L. Tsai and R. D. G. McKay, "A nucleolar mechanism controlling cell proliferation in stem cells and cancer cells," *Genes & Development*, vol. 16, no. 23, pp. 2991–3003, 2002.
- [75] L. Romanova, A. Grand, L. Zhang et al., "Critical role of nucleostemin in pre-rRNA processing," *The Journal of Biological Chemistry*, vol. 284, no. 8, pp. 4968–4977, 2009.
- [76] F. V. Fuller-Pace, "DExD/H box RNA helicases: multifunctional proteins with important roles in transcriptional regulation," *Nucleic Acids Research*, vol. 34, no. 15, pp. 4206–4215, 2006.
- [77] D. Henning, R. B. So, R. Jin, L. F. Lau, and B. C. Valdez, "Silencing of RNA helicase II/*Gua* inhibits mammalian ribosomal RNA production," *The Journal of Biological Chemistry*, vol. 278, no. 52, pp. 52307–52314, 2003.
- [78] Y. R. Lapik, C. J. Fernandes, L. F. Lau, and D. G. Pestov, "Physical and functional interaction between Pes1 and Bop1 in mammalian ribosome biogenesis," *Molecular Cell*, vol. 15, no. 1, pp. 17–29, 2004.
- [79] K. Wan, Y. Yabuki, and K. Mizuta, "Roles of Ebp2 and ribosomal protein L36 in ribosome biogenesis in *Saccharomyces cerevisiae*," *Current Genetics*, vol. 61, no. 1, pp. 31–41, 2015.
- [80] J. Roos, J. M. Luz, S. Centoducati, R. Sternglanz, and W. J. Lennarz, "ENP1, an essential gene encoding a nuclear protein that is highly conserved from yeast to humans," *Gene*, vol. 185, no. 1, pp. 137–146, 1997.
- [81] W. Chen, J. Bucaria, D. A. Band, A. Sutton, and R. Sternglanz, "Enp1, a yeast protein associated with U3 and U14 snoRNAs, is required for pre-rRNA processing and 40S subunit synthesis," *Nucleic Acids Research*, vol. 31, no. 2, pp. 690–699, 2003.
- [82] M. J. Stewart and E. K. Nordquist, "Drosophila Bys is nuclear and shows dynamic tissue-specific expression during development," *Development Genes and Evolution*, vol. 215, no. 2, pp. 97–102, 2005.
- [83] J. Sheng, S. Yang, L. Xu et al., "Bystin as a novel marker for reactive astrocytes in the adult rat brain following injury," *The European Journal of Neuroscience*, vol. 20, no. 4, pp. 873–884, 2004.
- [84] M. N. Fukuda, M. Miyoshi, and D. Nadano, "The role of bystin in embryo implantation and in ribosomal biogenesis,"

- Cellular and Molecular Life Sciences*, vol. 65, no. 1, pp. 92–99, 2008.
- [85] J. van Riggelen, A. Yetil, and D. W. Felsher, “MYC as a regulator of ribosome biogenesis and protein synthesis,” *Nature Reviews Cancer*, vol. 10, no. 4, pp. 301–309, 2010.
- [86] T. Sasaki, A. Toh-E, and Y. Kikuchi, “Yeast Krr1p physically and functionally interacts with a novel essential Kri1p, and both proteins are required for 40S ribosome biogenesis in the nucleolus,” *Molecular and Cellular Biology*, vol. 20, no. 21, pp. 7971–7979, 2000.
- [87] A.-C. Gavin, M. Bösch, R. Krause et al., “Functional organization of the yeast proteome by systematic analysis of protein complexes,” *Nature*, vol. 415, no. 6868, pp. 141–147, 2002.
- [88] D. Piekna-Przybylska, P. Przybylski, A. Baudin-Baillieu, J. P. Rousset, and M. J. Fournier, “Ribosome performance is enhanced by a rich cluster of pseudouridines in the A-site finger region of the large subunit,” *The Journal of Biological Chemistry*, vol. 283, no. 38, pp. 26026–26036, 2008.
- [89] S. Galardi, A. Fatica, A. Bachi, A. Scaloni, C. Presutti, and I. Bozzoni, “Purified box C/D snoRNPs are able to reproduce site-specific 2'-O-methylation of target RNA in vitro,” *Molecular and Cellular Biology*, vol. 22, no. 19, pp. 6663–6668, 2002.
- [90] N. J. Watkins and M. T. Bohnsack, “The box C/D and H/ACA snoRNPs: key players in the modification, processing and the dynamic folding of ribosomal RNA,” *Wiley Interdisciplinary Reviews RNA*, vol. 3, no. 3, pp. 397–414, 2012.
- [91] W. A. Decatur and M. J. Fournier, “rRNA modifications and ribosome function,” *Trends in Biochemical Sciences*, vol. 27, no. 7, pp. 344–351, 2002.
- [92] E. A. Caton, E. K. Kelly, R. Kamalampeta, and U. Kothe, “Efficient RNA pseudouridylation by eukaryotic H/ACA ribonucleoproteins requires high affinity binding and correct positioning of guide RNA,” *Nucleic Acids Research*, vol. 46, no. 2, pp. 905–916, 2018.
- [93] R. J. Ontiveros, J. Stoute, and K. F. Liu, “The chemical diversity of RNA modifications,” *Biochemical Journal*, vol. 476, no. 8, pp. 1227–1245, 2019.
- [94] M. R. Santoro, S. M. Bray, and S. T. Warren, “Molecular mechanisms of fragile X syndrome: a twenty-year perspective,” *Annual Review of Pathology*, vol. 7, no. 1, pp. 219–245, 2012.
- [95] Y. Li and X. Zhao, “Concise review: fragile X proteins in stem cell maintenance and differentiation,” *Stem Cells*, vol. 32, no. 7, pp. 1724–1733, 2014.
- [96] Y. Luo, G. Shan, W. Guo et al., “Fragile x mental retardation protein regulates proliferation and differentiation of adult neural stem/progenitor cells,” *PLoS Genetics*, vol. 6, no. 4, article e1000898, 2010.
- [97] M. Telias, M. Segal, and D. Ben-Yosef, “Neural differentiation of fragile X human embryonic stem cells reveals abnormal patterns of development despite successful neurogenesis,” *Developmental Biology*, vol. 374, no. 1, pp. 32–45, 2013.
- [98] M. Kim, M. Bellini, and S. Ceman, “Fragile X mental retardation protein FMRP binds mRNAs in the nucleus,” *Molecular and Cellular Biology*, vol. 29, no. 1, pp. 214–228, 2009.
- [99] M. S. Taha, K. Nouri, L. G. Milroy et al., “Subcellular fractionation and localization studies reveal a direct interaction of the fragile X mental retardation protein (FMRP) with nucleolin,” *PLoS One*, vol. 9, no. 3, article e91465, 2014.
- [100] S. Sharma and D. L. J. Lafontaine, “View from a bridge: a new perspective on eukaryotic rRNA base modification,” *Trends in Biochemical Sciences*, vol. 40, no. 10, pp. 560–575, 2015.
- [101] M. N. D'Souza, N. K. C. Gowda, V. Tiwari et al., “FMRP interacts with C/D Box snoRNA in the nucleus and regulates ribosomal RNA methylation,” *iScience*, vol. 9, pp. 399–411, 2018.
- [102] E. Chen, M. R. Sharma, X. Shi, R. K. Agrawal, and S. Joseph, “Fragile X mental retardation protein regulates translation by binding directly to the ribosome,” *Molecular Cell*, vol. 54, no. 3, pp. 407–417, 2014.
- [103] A. Sharma, C. A. Hoeffler, Y. Takayasu et al., “Dysregulation of mTOR signaling in fragile X syndrome,” *The Journal of Neuroscience*, vol. 30, no. 2, pp. 694–702, 2010.
- [104] N. Weng, I. J. Weiler, A. Sumis, E. Berry-Kravis, and W. T. Greenough, “Early-phase ERK activation as a biomarker for metabolic status in fragile X syndrome,” *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, vol. 147b, no. 7, pp. 1253–1257, 2008.
- [105] T. G. Lohith, E. K. Osterweil, M. Fujita, K. J. Jenko, M. F. Bear, and R. B. Innis, “Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome?,” *Molecular Autism*, vol. 4, no. 1, p. 15, 2013.
- [106] C. Gross, M. Nakamoto, X. Yao et al., “Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome,” *The Journal of Neuroscience*, vol. 30, no. 32, pp. 10624–10638, 2010.
- [107] G. Recher, J. Jouralet, A. Brombin et al., “Zebrafish midbrain slow-amplifying progenitors exhibit high levels of transcripts for nucleotide and ribosome biogenesis,” *Development*, vol. 140, no. 24, pp. 4860–4869, 2013.
- [108] V. Marcel, S. E. Ghayad, S. Belin et al., “p53 acts as a safeguard of translational control by regulating fibrillarin and rRNA methylation in cancer,” *Cancer Cell*, vol. 24, no. 3, pp. 318–330, 2013.
- [109] R.-W. Yao, G. Xu, Y. Wang et al., “Nascent pre-rRNA sorting via phase separation drives the assembly of dense fibrillar components in the human nucleolus,” *Molecular Cell*, vol. 76, no. 5, pp. 767–783.e11, 2019.
- [110] H. Wang, D. Boisvert, K. K. Kim, R. Kim, and S. H. Kim, “Crystal structure of a fibrillar homologue from *Methanococcus jannaschii*, a hyperthermophile, at 1.6 Å resolution,” *The EMBO Journal*, vol. 19, no. 3, pp. 317–323, 2000.
- [111] M. Y. Shubina, Y. R. Musinova, and E. V. Sheval, “Proliferation, cancer, and aging-novel functions of the nucleolar methyltransferase fibrillarin?,” *Cell Biology International*, vol. 42, no. 11, pp. 1463–1466, 2018.
- [112] M. Y. Shubina, Y. R. Musinova, and E. V. Sheval, “Nucleolar methyltransferase fibrillarin: evolution of structure and functions,” *Biochemistry Biokhimiia*, vol. 81, no. 9, pp. 941–950, 2016.
- [113] S. Ramagopal, “The Dictyostelium ribosome: biochemistry, molecular biology, and developmental regulation,” *Biochemistry and Cell Biology*, vol. 70, no. 9, pp. 738–750, 1992.
- [114] Z. Shi and M. Barna, “Translating the genome in time and space: specialized ribosomes, RNA regulons, and RNA-binding proteins,” *Annual Review of Cell and Developmental Biology*, vol. 31, no. 1, pp. 31–54, 2015.
- [115] J. E. Gerst, “Pimp my ribosome: ribosomal protein paralogs specify translational control,” *Trends in Genetics*, vol. 34, no. 11, pp. 832–845, 2018.

- [116] N. Kondrashov, A. Pusic, C. R. Stumpf et al., "Ribosome-mediated specificity in Hox mRNA translation and vertebrate tissue patterning," *Cell*, vol. 145, no. 3, pp. 383–397, 2011.
- [117] D. Boehringer, R. Thermann, A. Ostareck-Lederer, J. D. Lewis, and H. Stark, "Structure of the Hepatitis C Virus IRES Bound to the Human 80S Ribosome: remodeling of the HCV IRES," *Structure*, vol. 13, no. 11, pp. 1695–1706, 2005.
- [118] C. M. T. Spahn, E. Jan, A. Mulder, R. A. Grassucci, P. Sarnow, and J. Frank, "Cryo-EM visualization of a viral internal ribosome entry site bound to human ribosomes: the IRES functions as an RNA-based translation factor," *Cell*, vol. 118, no. 4, pp. 465–475, 2004.
- [119] I. S. Fernández, X. C. Bai, G. Murshudov, S. H. W. Scheres, and V. Ramakrishnan, "Initiation of translation by cricket paralysis virus IRES requires its translocation in the ribosome," *Cell*, vol. 157, no. 4, pp. 823–831, 2014.
- [120] J. S. Kieft, "Viral IRES RNA structures and ribosome interactions," *Trends in Biochemical Sciences*, vol. 33, no. 6, pp. 274–283, 2008.
- [121] D. Iskander, B. Psaila, G. Gerrard et al., "Elucidation of the EP defect in Diamond-Blackfan anemia by characterization and prospective isolation of human EPs," *Blood*, vol. 125, no. 16, pp. 2553–2557, 2015.
- [122] L. Mirabello, P. P. Khincha, S. R. Ellis et al., "Novel and known ribosomal causes of Diamond-Blackfan anaemia identified through comprehensive genomic characterisation," *Journal of Medical Genetics*, vol. 54, no. 6, pp. 417–425, 2017.
- [123] R. Horos, H. Ijspeert, D. Pospisilova et al., "Ribosomal deficiencies in Diamond-Blackfan anemia impair translation of transcripts essential for differentiation of murine and human erythroblasts," *Blood*, vol. 119, no. 1, pp. 262–272, 2012.
- [124] J. A. Ribeil, Y. Zermati, J. Vandekerckhove et al., "Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1," *Nature*, vol. 445, no. 7123, pp. 102–105, 2007.
- [125] V. G. Sankaran, R. Ghazvinian, R. Do et al., "Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia," *The Journal of Clinical Investigation*, vol. 122, no. 7, pp. 2439–2443, 2012.
- [126] C. Zhou, D. Zang, Y. Jin et al., "Mutation in ribosomal protein L21 underlies hereditary hypotrachosis simplex," *Human Mutation*, vol. 32, no. 7, pp. 710–714, 2011.
- [127] C. G. Sanchez, F. K. Teixeira, B. Czech et al., "Regulation of ribosome biogenesis and protein synthesis controls germline stem cell differentiation," *Cell Stem Cell*, vol. 18, no. 2, pp. 276–290, 2016.
- [128] M. Kobayashi, S. Oshima, C. Maeyashiki et al., "The ubiquitin hybrid gene *UBA52* regulates ubiquitination of ribosome and sustains embryonic development," *Scientific Reports*, vol. 6, no. 1, article 36780, 2016.
- [129] M. E. Valk-Lingbeek, S. W. M. Bruggeman, and M. van Lohuizen, "Stem cells and cancer: the polycomb connection," *Cell*, vol. 118, no. 4, pp. 409–418, 2004.
- [130] A. Sparmann and M. van Lohuizen, "Polycomb silencers control cell fate, development and cancer," *Nature Reviews Cancer*, vol. 6, no. 11, pp. 846–856, 2006.
- [131] A. P. Bracken and K. Helin, "Polycomb group proteins: navigators of lineage pathways led astray in cancer," *Nature Reviews Cancer*, vol. 9, no. 11, pp. 773–784, 2009.
- [132] Y. Jung and J. A. Nolta, "BMI1 regulation of self-renewal and multipotency in human mesenchymal stem cells," *Current Stem Cell Research & Therapy*, vol. 11, no. 2, pp. 131–140, 2016.
- [133] M. Ganapathi, N. C. Boles, C. Charniga et al., "Effect of Bmi1 over-expression on gene expression in adult and embryonic murine neural stem cells," *Scientific Reports*, vol. 8, no. 1, article 7464, 2018.
- [134] R. Gao, S. Chen, M. Kobayashi et al., "Bmi1 promotes erythroid development through regulating ribosome biogenesis," *Stem Cells*, vol. 33, no. 3, pp. 925–938, 2015.
- [135] P. Jaako, J. Flygare, K. Olsson et al., "Mice with ribosomal protein S19 deficiency develop bone marrow failure and symptoms like patients with Diamond-Blackfan anemia," *Blood*, vol. 118, no. 23, pp. 6087–6096, 2011.
- [136] D. W. Young, M. Q. Hassan, J. Pratap et al., "Mitotic occupancy and lineage-specific transcriptional control of *rRNA* genes by Runx2," *Nature*, vol. 445, no. 7126, pp. 442–446, 2007.
- [137] G. Juban, G. Giraud, B. Guyot et al., "Spi-1 and Fli-1 directly activate common target genes involved in ribosome biogenesis in Friend erythroleukemic cells," *Molecular and Cellular Biology*, vol. 29, no. 10, pp. 2852–2864, 2009.
- [138] D. Beck, J. A. I. Thoms, D. Perera et al., "Genome-wide analysis of transcriptional regulators in human HSPCs reveals a densely interconnected network of coding and noncoding genes," *Blood*, vol. 122, no. 14, pp. e12–e22, 2013.
- [139] C. V. Dang, "MYC on the Path to Cancer," *Cell*, vol. 149, no. 1, pp. 22–35, 2012.
- [140] M. Yu, T. Mazor, H. Huang et al., "Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors," *Molecular Cell*, vol. 45, no. 3, pp. 330–343, 2012.
- [141] A. Sathe and R. Nawroth, "Targeting the PI3K/AKT/mTOR pathway in bladder cancer," *Methods in Molecular Biology*, vol. 1655, pp. 335–350, 2018.
- [142] X. Li, C. Wu, N. Chen et al., "PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma," *Oncotarget*, vol. 7, no. 22, pp. 33440–33450, 2016.
- [143] A. S. Alzahrani, "PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside," *Seminars in Cancer Biology*, vol. 59, pp. 125–132, 2019.
- [144] L. M. Neri, A. Cani, A. M. Martelli et al., "Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential," *Leukemia*, vol. 28, no. 4, pp. 739–748, 2014.
- [145] W. Zhang, G. Feng, L. Wang et al., "MeCP2 deficiency promotes cell reprogramming by stimulating IGF1/AKT/mTOR signaling and activating ribosomal protein-mediated cell cycle gene translation," *Journal of Molecular Cell Biology*, vol. 10, no. 6, pp. 515–526, 2018.
- [146] H. Nojima, C. Tokunaga, S. Eguchi et al., "The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif," *The Journal of Biological Chemistry*, vol. 278, no. 18, pp. 15461–15464, 2003.
- [147] N. Siddiqui and N. Sonenberg, "Signalling to eIF4E in cancer," *Biochemical Society Transactions*, vol. 43, no. 5, pp. 763–772, 2015.
- [148] X. Qin, B. Jiang, and Y. Zhang, "4E-BP1, a multifactor regulated multifunctional protein," *Cell Cycle*, vol. 15, no. 6, pp. 781–786, 2016.

- [149] B. Magnuson, B. Ekim, and D. C. Fingar, "Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks," *The Biochemical Journal*, vol. 441, no. 1, pp. 1–21, 2012.
- [150] M. R. Tavares, I. C. B. Pavan, C. L. Amaral, L. Meneguello, A. D. Luchessi, and F. M. Simabuco, "The S6K protein family in health and disease," *Life Sciences*, vol. 131, pp. 1–10, 2015.
- [151] M. Murakami, T. Ichisaka, M. Maeda et al., "mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells," *Molecular and Cellular Biology*, vol. 24, no. 15, pp. 6710–6718, 2004.
- [152] K. Takahashi, M. Murakami, and S. Yamanaka, "Role of the phosphoinositide 3-kinase pathway in mouse embryonic stem (ES) cells," *Biochemical Society Transactions*, vol. 33, no. 6, pp. 1522–1525, 2005.
- [153] A. Bulut-Karslioglu, S. Biechele, H. Jin et al., "Inhibition of mTOR induces a paused pluripotent state," *Nature*, vol. 540, no. 7631, pp. 119–123, 2016.
- [154] C. J. Granier, W. Wang, T. Tsang et al., "Conditional inactivation of PDCD2 induces p53 activation and cell cycle arrest," *Biol Open*, vol. 3, no. 9, pp. 821–831, 2014.
- [155] W. Mu, R. J. Munroe, A. K. Barker, and J. C. Schimenti, "PDCD2 is essential for inner cell mass development and embryonic stem cell maintenance," *Developmental Biology*, vol. 347, no. 2, pp. 279–288, 2010.
- [156] J. Kramer, C. J. Granier, S. Davis et al., "PDCD2 controls hematopoietic stem cell differentiation during development," *Stem Cells and Development*, vol. 22, no. 1, pp. 58–72, 2013.
- [157] N. Barboza, S. Minakhina, D. J. Medina et al., "PDCD2 functions in cancer cell proliferation and predicts relapsed leukemia," *Cancer Biology & Therapy*, vol. 14, no. 6, pp. 546–555, 2014.
- [158] S. Minakhina and R. Steward, "Hematopoietic stem cells in *Drosophila*," *Development*, vol. 137, no. 1, pp. 27–31, 2009.
- [159] A. M. Burroughs and L. Aravind, "Analysis of two domains with novel RNA-processing activities throws light on the complex evolution of ribosomal RNA biogenesis," *Frontiers in Genetics*, vol. 5, p. 424, 2014.
- [160] S. Minakhina, T. Naryshkina, N. Changela, W. Tan, and R. Steward, "Zfrp8/PDCD2 interacts with Rps2 connecting ribosome maturation and gene-specific translation," *PLoS One*, vol. 11, no. 1, article e0147631, 2016.
- [161] J. Rabl, M. Leibundgut, S. F. Ataide, A. Haag, and N. Ban, "Crystal structure of the eukaryotic 40S ribosomal subunit in complex with initiation factor 1," *Science*, vol. 331, no. 6018, pp. 730–736, 2011.
- [162] B. S. Strunk, C. R. Loucks, M. Su et al., "Ribosome assembly factors prevent premature translation initiation by 40S assembly intermediates," *Science*, vol. 333, no. 6048, pp. 1449–1453, 2011.
- [163] L. Wan, T. C. Dockendorff, T. A. Jongens, and G. Dreyfuss, "Characterization of dFMR1, a *Drosophila melanogaster* homolog of the fragile X mental retardation protein," *Molecular and Cellular Biology*, vol. 20, no. 22, pp. 8536–8547, 2000.
- [164] W. Tan, C. Schauder, T. Naryshkina, S. Minakhina, and R. Steward, "Zfrp8 forms a complex with fragile-X mental retardation protein and regulates its localization and function," *Developmental Biology*, vol. 410, no. 2, pp. 202–212, 2016.
- [165] B. Bardoni, R. Willemsen, I. J. Weiler et al., "NUFIP1 (nuclear FMRP interacting protein 1) is a nucleocytoplasmic shuttling protein associated with active synaptoneuroosomes," *Experimental Cell Research*, vol. 289, no. 1, pp. 95–107, 2003.
- [166] S.-T. Mullineux and D. L. J. Lafontaine, "Mapping the cleavage sites on mammalian pre-rRNAs: where do we stand?," *Biochimie*, vol. 94, no. 7, pp. 1521–1532, 2012.
- [167] O. Esakova and A. S. Krasilnikov, "Of proteins and RNA: the RNase P/MRP family," *RNA*, vol. 16, no. 9, pp. 1725–1747, 2010.
- [168] H. Gingold, D. Tehler, N. R. Christoffersen et al., "A dual program for translation regulation in cellular proliferation and differentiation," *Cell*, vol. 158, no. 6, pp. 1281–1292, 2014.
- [169] I. Topisirovic and N. Sonenberg, "Distinctive tRNA repertoires in proliferating versus differentiating cells," *Cell*, vol. 158, no. 6, pp. 1238–1239, 2014.
- [170] K. Takahashi and S. Yamanaka, "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors," *Cell*, vol. 126, no. 4, pp. 663–676, 2006.
- [171] M. Stadtfeld and K. Hochedlinger, "Induced pluripotency: history, mechanisms, and applications," *Genes & Development*, vol. 24, no. 20, pp. 2239–2263, 2010.
- [172] T. Ma, M. Xie, T. Laurent, and S. Ding, "Progress in the reprogramming of somatic cells," *Circulation Research*, vol. 112, no. 3, pp. 562–574, 2013.
- [173] S. Hu and G. Shan, "LncRNAs in stem cells," *Stem Cells International*, vol. 2016, Article ID 2681925, 8 pages, 2016.
- [174] S. Zhang, Y. Wang, L. Jia et al., "Profiling the long noncoding RNA interaction network in the regulatory elements of target genes by chromatin in situ reverse transcription sequencing," *Genome Research*, vol. 29, no. 9, pp. 1521–1532, 2019.
- [175] C. Wang, L. Jia, Y. Wang et al., "Genome-wide interaction target profiling reveals a novel Peblr20-eRNA activation pathway to control stem cell pluripotency," *Theranostics*, vol. 10, no. 1, pp. 353–370, 2020.